Treg Therapy in Subclinical Inflammation in Kidney Transplantation

NCT02711826 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is:

* To see if polyTregs can reduce inflammation in a transplanted kidney.
* To find out what effects, good or bad, polyTregs will have in the kidney recipient.
* To find out what effects, good or bad, taking everolimus after polyTregs will have in the kidney recipient.

Conditions

  • Kidney Transplant
  • Adult Living Donor Kidney Transplant Recipients
  • Renal Transplant
  • Living Kidney Donor

Interventions

BIOLOGICAL

Polyclonal Regulatory T Cells

Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.

DRUG

Everolimus

DRUG

Tacrolimus

DRUG

Mycophenolate mofetil

All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.

DRUG

Mycophenolic acid

All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.

DRUG

Acetaminophen

650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.

DRUG

Diphenhydramine

25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.

PROCEDURE

Biopsy, Kidney

PROCEDURE

Blood Draw

PROCEDURE

Leukapheresis

PROCEDURE

IS regimen conversion

Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.

Sponsors & Collaborators

  • Clinical Trials in Organ Transplantation

    collaborator NETWORK
  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Flavio Vincenti, MD · University of California at San Francisco

  • Sindhu Chandran, MD · University of California at San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2023-08-04
Completion
2023-08-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711826 on ClinicalTrials.gov